US5736146A
(en)
*
|
1992-07-30 |
1998-04-07 |
Yeda Research And Development Co. Ltd. |
Conjugates of poorly immunogenic antigens and synthetic peptide carriers and vaccines comprising them
|
IL102687A
(en)
*
|
1992-07-30 |
1997-06-10 |
Yeda Res & Dev |
Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
|
PT700445E
(pt)
*
|
1993-06-04 |
2002-07-31 |
Whitehead Biomedical Inst |
Proteinas de stress e suas utilizacoes
|
AUPM322393A0
(en)
*
|
1993-12-24 |
1994-01-27 |
Austin Research Institute, The |
Mucin carbohydrate compounds and their use in immunotherapy
|
US5750119A
(en)
*
|
1994-01-13 |
1998-05-12 |
Mount Sinai School Of Medicine Of The City University Of New York |
Immunotherapeutic stress protein-peptide complexes against cancer
|
US5997873A
(en)
|
1994-01-13 |
1999-12-07 |
Mount Sinai School Of Medicine Of The City University Of New York |
Method of preparation of heat shock protein 70-peptide complexes
|
US5961979A
(en)
|
1994-03-16 |
1999-10-05 |
Mount Sinai School Of Medicine Of The City University Of New York |
Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
|
US5869058A
(en)
*
|
1994-05-25 |
1999-02-09 |
Yeda Research And Development Co. Ltd. |
Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines
|
IL109790A0
(en)
*
|
1994-05-25 |
1994-08-26 |
Yeda Res & Dev |
Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines
|
GB9422096D0
(en)
*
|
1994-11-02 |
1994-12-21 |
Biocine Spa |
Combined meningitis vaccine
|
US6548643B1
(en)
|
1994-11-16 |
2003-04-15 |
Austin Research Institute |
Antigen carbohydrate compounds and their use in immunotherapy
|
US8021667B2
(en)
|
1994-11-16 |
2011-09-20 |
Macfarlane Burnet Institute For Medical Research And Public Health Ltd |
Compositions for immunotherapy and uses thereof
|
EP0832238A1
(de)
*
|
1995-06-07 |
1998-04-01 |
Biochem Vaccines Inc. |
Streptokokken-hitzeschock-proteine, mitglieder der hsp70-familie
|
US6331299B1
(en)
|
1995-08-18 |
2001-12-18 |
Sloan-Kettering Institute For Cancer Research |
Method for treatment of cancer and infectious disease and compositions useful in same
|
US6761892B1
(en)
|
1995-08-18 |
2004-07-13 |
Sloan-Kettering Institute For Cancer Research |
Heat shock protein-based vaccines and immunotherapies
|
US6719974B1
(en)
|
1995-08-18 |
2004-04-13 |
Sloan-Kettering Institute For Cancer Research |
Heat shock protein-based vaccines and immunotherapies
|
US6773707B1
(en)
|
1995-08-18 |
2004-08-10 |
Sloan-Kettering Institute For Cancer Research |
Heat shock protein-based vaccines and immunotherapies
|
CA2229595A1
(en)
*
|
1995-08-18 |
1997-02-27 |
Sloan-Kettering Institute For Cancer Research |
Method for treatment of cancer and infectious diseases and compositions useful in same
|
US5985270A
(en)
*
|
1995-09-13 |
1999-11-16 |
Fordham University |
Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
|
US5935576A
(en)
*
|
1995-09-13 |
1999-08-10 |
Fordham University |
Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
|
AU727673B2
(en)
*
|
1995-09-13 |
2000-12-21 |
Fordham University |
Therapeutic and prophylactic methods using heat shock proteins
|
US5837251A
(en)
|
1995-09-13 |
1998-11-17 |
Fordham University |
Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
|
ES2283012T3
(es)
*
|
1996-01-04 |
2007-10-16 |
Novartis Vaccines And Diagnostics, Inc. |
Bacterioferritina de helicobacter pylori.
|
US6451541B1
(en)
*
|
1996-05-14 |
2002-09-17 |
Ernst-Ludwig Winnacker |
Chaperones capable of binding to prion proteins and distinguishing the isoforms PrPc and PrPsc
|
US7157089B1
(en)
|
1996-11-26 |
2007-01-02 |
Stressgen Biotechnologies Corporation |
Immune responses using compositions containing stress proteins
|
US6017540A
(en)
|
1997-02-07 |
2000-01-25 |
Fordham University |
Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
|
US5830464A
(en)
*
|
1997-02-07 |
1998-11-03 |
Fordham University |
Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
|
EP1047451A1
(de)
*
|
1997-02-18 |
2000-11-02 |
Whitehead Institute For Biomedical Research |
Verwendung von hitzeshockproteinen zur verabreichung von einheiten in zellen
|
DK1002110T3
(da)
|
1997-08-05 |
2003-05-26 |
Stressgen Biotechnologies Corp |
Immunsvar mod HPV-antigener fremkaldt af sammensætninger, som omfatter et HPV-antigen og et stressprotein eller en ekspressionsvektor i stand til at ekspressere disse proteiner
|
DK1027063T3
(da)
|
1997-09-29 |
2009-06-02 |
Macfarlane Burnet Inst For Med |
Mannosereceptorbærende cellelinje og antigensammensætning
|
US5948646A
(en)
|
1997-12-11 |
1999-09-07 |
Fordham University |
Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
|
JP4768122B2
(ja)
|
1998-02-20 |
2011-09-07 |
ユニバーシティー オブ マイアミ |
改変型熱ショックタンパク質−抗原性ペプチド複合体
|
US6497880B1
(en)
|
1998-12-08 |
2002-12-24 |
Stressgen Biotechnologies Corporation |
Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus
|
US6495347B1
(en)
|
1999-07-08 |
2002-12-17 |
Stressgen Biotechnologies Corporation |
Induction of a Th1-like response in vitro
|
EP1253939B1
(de)
*
|
2000-01-14 |
2009-08-05 |
Whitehead Institute For Biomedical Research |
Induktion zytotoxischer lymphozyten durch hitzeschockprotein-fusionsproteine hängt von der atp-bindungsdomäne in hsp ab und is cd4+ unabhängig
|
EP1286693A4
(de)
|
2000-06-02 |
2005-07-13 |
Univ Connecticut Health Ct |
Komplexe aus alpha-2-makroglobulin und antigenen molekülen zur immuntherapie
|
CZ20024154A3
(cs)
|
2000-06-26 |
2003-08-13 |
Stressgen Biotechnologies Corporation |
Použití prostředku obsahujícího napojený protein pro výrobu farmaceutického přípravku pro léčení bradavic a chorob a stavů souvisejících s papiloma virem
|
EP2277894A1
(de)
|
2000-10-27 |
2011-01-26 |
Novartis Vaccines and Diagnostics S.r.l. |
Nukleinsäure und Proteine von Gruppen A und B Streptokokken
|
US7082569B2
(en)
|
2001-01-17 |
2006-07-25 |
Outlooksoft Corporation |
Systems and methods providing dynamic spreadsheet functionality
|
BR0206995A
(pt)
|
2001-02-05 |
2005-08-16 |
Stressgen Biotechnologies Corp |
Tratamento do vìrus da hepatite b
|
GB0107658D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Streptococcus pneumoniae
|
GB0107661D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Staphylococcus aureus
|
GB0115176D0
(en)
|
2001-06-20 |
2001-08-15 |
Chiron Spa |
Capular polysaccharide solubilisation and combination vaccines
|
GB0118249D0
(en)
|
2001-07-26 |
2001-09-19 |
Chiron Spa |
Histidine vaccines
|
GB0121591D0
(en)
|
2001-09-06 |
2001-10-24 |
Chiron Spa |
Hybrid and tandem expression of neisserial proteins
|
CN1635896A
(zh)
|
2001-08-20 |
2005-07-06 |
康涅狄格大学健康中心 |
包含用于治疗癌症及感染性疾病的热休克蛋白或α2-巨球蛋白的组合物制备方法
|
ES2386386T3
(es)
|
2001-12-12 |
2012-08-20 |
Novartis Vaccines And Diagnostics S.R.L. |
Inmunización contra Chlamydia trachomatis
|
JP4646516B2
(ja)
|
2002-02-20 |
2011-03-09 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
吸着したポリペプチド含有分子を有する微粒子
|
DE60328481D1
(de)
|
2002-05-14 |
2009-09-03 |
Novartis Vaccines & Diagnostic |
Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthält
|
GB0220194D0
(en)
|
2002-08-30 |
2002-10-09 |
Chiron Spa |
Improved vesicles
|
CN1809380B
(zh)
|
2002-10-11 |
2010-05-12 |
启龙有限公司 |
广泛防御高毒性脑膜炎球菌谱系的多肽-疫苗
|
LT1556477T
(lt)
|
2002-11-01 |
2017-10-25 |
Glaxosmithkline Biologicals S.A. |
Džiovinimo būdas
|
US20070059329A1
(en)
|
2002-11-15 |
2007-03-15 |
Nathalie Norais |
Unexpected surface proteins in meningococcus
|
GB0227346D0
(en)
|
2002-11-22 |
2002-12-31 |
Chiron Spa |
741
|
EP2263687B1
(de)
|
2002-12-27 |
2015-03-25 |
Novartis Vaccines and Diagnostics, Inc. |
Immunogene zusammensetzungen enthaltend phospholipid
|
CN102319427A
(zh)
|
2003-01-30 |
2012-01-18 |
诺华疫苗和诊断有限公司 |
抗多种脑膜炎球菌血清组的可注射性疫苗
|
US7420037B2
(en)
|
2003-02-13 |
2008-09-02 |
Antigenics Inc. |
Heat shock protein-based vaccines and immunotherapies
|
US7893096B2
(en)
|
2003-03-28 |
2011-02-22 |
Novartis Vaccines And Diagnostics, Inc. |
Use of small molecule compounds for immunopotentiation
|
US7309491B2
(en)
|
2003-04-11 |
2007-12-18 |
Antigenics Inc. |
Heat shock protein-based vaccines and immunotherapies
|
CN1798548B
(zh)
|
2003-06-02 |
2010-05-05 |
诺华疫苗和诊断公司 |
基于含吸附类毒素和含多糖抗原微粒体的免疫原性组合物
|
GB0323103D0
(en)
|
2003-10-02 |
2003-11-05 |
Chiron Srl |
De-acetylated saccharides
|
RU2378010C2
(ru)
|
2003-10-02 |
2010-01-10 |
Новартис Вэксинес Энд Дайэгностикс С.Р.Л. |
Жидкие вакцины для множественных серогрупп менингококков
|
GB0406013D0
(en)
|
2004-03-17 |
2004-04-21 |
Chiron Srl |
Analysis of saccharide vaccines without interference
|
GB0408978D0
(en)
|
2004-04-22 |
2004-05-26 |
Chiron Srl |
Meningococcal fermentation for preparing conjugate vaccines
|
GB0409745D0
(en)
|
2004-04-30 |
2004-06-09 |
Chiron Srl |
Compositions including unconjugated carrier proteins
|
GB0410866D0
(en)
|
2004-05-14 |
2004-06-16 |
Chiron Srl |
Haemophilius influenzae
|
GB0411387D0
(en)
|
2004-05-21 |
2004-06-23 |
Chiron Srl |
Analysis of saccharide length
|
GB0413868D0
(en)
|
2004-06-21 |
2004-07-21 |
Chiron Srl |
Dimensional anlaysis of saccharide conjugates
|
CA2571421A1
(en)
|
2004-06-24 |
2006-01-05 |
Nicholas Valiante |
Compounds for immunopotentiation
|
US20110104186A1
(en)
|
2004-06-24 |
2011-05-05 |
Nicholas Valiante |
Small molecule immunopotentiators and assays for their detection
|
WO2006078318A2
(en)
|
2004-07-29 |
2006-07-27 |
Novartis Vaccines And Diagnostics Inc. |
Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
|
GB0424092D0
(en)
|
2004-10-29 |
2004-12-01 |
Chiron Srl |
Immunogenic bacterial vesicles with outer membrane proteins
|
GB0502095D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Conjugation of streptococcal capsular saccharides
|
GB0502096D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Purification of streptococcal capsular polysaccharide
|
HUE027400T2
(en)
|
2005-02-18 |
2016-10-28 |
Glaxosmithkline Biologicals Sa |
Proteins and nucleic acids from meningitis / sepsis with Escherichia coli
|
CA2598488A1
(en)
|
2005-02-18 |
2006-08-31 |
Novartis Vaccines And Diagnostics, Inc. |
Immunogens from uropathogenic escherichia coli
|
GB0505518D0
(en)
*
|
2005-03-17 |
2005-04-27 |
Chiron Srl |
Combination vaccines with whole cell pertussis antigen
|
US8119146B2
(en)
|
2005-04-18 |
2012-02-21 |
Angelica Medina-Selby |
Expressing hepatitis B virus surface antigen for vaccine preparation
|
MX2007016402A
(es)
|
2005-06-27 |
2008-03-07 |
Glaxosmithkline Biolog Sa |
Composicion inmunogenica.
|
CN101287488B
(zh)
|
2005-09-01 |
2013-01-30 |
诺华疫苗和诊断有限两合公司 |
含血清群c脑膜炎球菌的多价疫苗
|
GB0522303D0
(en)
|
2005-11-01 |
2005-12-07 |
Chiron Srl |
Culture method
|
GB0522765D0
(en)
|
2005-11-08 |
2005-12-14 |
Chiron Srl |
Combination vaccine manufacture
|
EP1969001A2
(de)
|
2005-11-22 |
2008-09-17 |
Novartis Vaccines and Diagnostics, Inc. |
Norovirus- und sapovirus-antigene
|
GB0524066D0
(en)
|
2005-11-25 |
2006-01-04 |
Chiron Srl |
741 ii
|
GB0607088D0
(en)
|
2006-04-07 |
2006-05-17 |
Glaxosmithkline Biolog Sa |
Vaccine
|
NO345368B1
(no)
|
2005-12-22 |
2021-01-04 |
Glaxosmithkline Biologicals Sa |
Streptococcus pneumoniae immunogen sammensetning for anvendelse ved behandling eller forebygging av sykdommer forårsaket av Streptococcus pneumoniae infeksjon ved serotype 19A-stammer.
|
GB0605757D0
(en)
|
2006-03-22 |
2006-05-03 |
Chiron Srl |
Separation of conjugated and unconjugated components
|
SI2004225T1
(sl)
|
2006-03-22 |
2012-08-31 |
Novartis Ag |
Reĺ˝imi za imunizacijo z meningokoknimi konjugati
|
EP2357184B1
(de)
|
2006-03-23 |
2015-02-25 |
Novartis AG |
Imidazochinoxalinverbindungen als Immunmodulatoren
|
WO2007116409A2
(en)
*
|
2006-04-11 |
2007-10-18 |
Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science |
Improved vaccines comprising multimeric hsp60 peptide carriers
|
US20100015168A1
(en)
|
2006-06-09 |
2010-01-21 |
Novartis Ag |
Immunogenic compositions for streptococcus agalactiae
|
GB0612854D0
(en)
|
2006-06-28 |
2006-08-09 |
Novartis Ag |
Saccharide analysis
|
CA2659552A1
(en)
|
2006-08-16 |
2008-02-21 |
Novartis Ag |
Immunogens from uropathogenic escherichia coli
|
BRPI0716518B8
(pt)
|
2006-09-07 |
2021-05-25 |
Glaxosmithkline Biologicals Sa |
vacina de ipv e uso da mesma
|
GB0700136D0
(en)
|
2007-01-04 |
2007-02-14 |
Glaxosmithkline Biolog Sa |
Process for manufacturing vaccines
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
US20100074918A1
(en)
|
2007-05-02 |
2010-03-25 |
Jan Poolman |
Vaccine
|
CN101784282B
(zh)
|
2007-06-26 |
2015-07-08 |
葛兰素史密丝克莱恩生物有限公司 |
包含肺炎链球菌荚膜多糖缀合物的疫苗
|
GB0713880D0
(en)
|
2007-07-17 |
2007-08-29 |
Novartis Ag |
Conjugate purification
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
AU2008299376B2
(en)
|
2007-09-12 |
2013-02-28 |
Glaxosmithkline Biologicals S.A. |
GAS57 mutant antigens and GAS57 antibodies
|
EP2200642B1
(de)
|
2007-10-19 |
2012-04-18 |
Novartis AG |
Meningokokkenimpfstoffformulierungen
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
AU2008339551B2
(en)
|
2007-12-21 |
2013-10-24 |
Glaxosmithkline Biologicals S.A. |
Mutant forms of streptolysin O
|
NZ587382A
(en)
|
2008-02-21 |
2012-01-12 |
Novartis Ag |
Meningococcal fhbp polypeptides
|
ES2460899T3
(es)
|
2008-03-03 |
2014-05-14 |
The University Of Miami |
Inmunoterapia basada en células cancerosas alógenas
|
KR20110017356A
(ko)
|
2008-03-20 |
2011-02-21 |
유니버시티 오브 마이애미 |
열충격 단백질 gp96 백신접종 및 이를 사용하는 방법
|
CA2777837C
(en)
|
2008-10-27 |
2017-07-11 |
Novartis Ag |
Purification method
|
GB0822634D0
(en)
|
2008-12-11 |
2009-01-21 |
Novartis Ag |
Meningitis vaccines
|
GB0822633D0
(en)
|
2008-12-11 |
2009-01-21 |
Novartis Ag |
Formulation
|
WO2010070453A2
(en)
|
2008-12-17 |
2010-06-24 |
Novartis Ag |
Meningococcal vaccines including hemoglobin receptor
|
CA2748788C
(en)
|
2009-01-05 |
2021-02-09 |
Epitogenesis Inc. |
The use of a composition comprising mustard oil, catechin, and vitamin a for modulating an immune response
|
CN103897045A
(zh)
|
2009-01-12 |
2014-07-02 |
诺华股份有限公司 |
抗革兰氏阳性细菌疫苗中的Cna_B结构域
|
SI2411048T1
(sl)
|
2009-03-24 |
2020-08-31 |
Glaxosmithkline Biologicals Sa |
Meningokokni faktor H vezavni protein uporabljen kot adjuvans
|
CA2756533A1
(en)
|
2009-03-24 |
2010-09-30 |
Novartis Ag |
Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
|
BRPI1013780B8
(pt)
|
2009-04-14 |
2022-10-04 |
Novartis Ag |
Composição imunogênica útil para imunização contra staphylococcus aureus, seu método de preparação e composição farmacêutica
|
BRPI1014494A2
(pt)
|
2009-04-30 |
2016-08-02 |
Coley Pharm Group Inc |
vacina pneumocócica e usos da mesma
|
WO2010132833A1
(en)
|
2009-05-14 |
2010-11-18 |
The Regents Of The University Of Michigan |
Streptococcus vaccine compositions and methods of using the same
|
ES2562259T3
(es)
|
2009-08-27 |
2016-03-03 |
Glaxosmithkline Biologicals Sa |
Polipéptidos híbridos que incluyen secuencias fHBP meningocócicas
|
SG178447A1
(en)
|
2009-09-03 |
2012-03-29 |
Pfizer Vaccines Llc |
Pcsk9 vaccine
|
AU2010293902A1
(en)
|
2009-09-10 |
2012-03-22 |
Novartis Ag |
Combination vaccines against respiratory tract diseases
|
CA2776004A1
(en)
|
2009-09-30 |
2011-04-07 |
Novartis Ag |
Expression of meningococcal fhbp polypeptides
|
JP2013506651A
(ja)
|
2009-09-30 |
2013-02-28 |
ノバルティス アーゲー |
Staphylococcus.aureus5型および8型莢膜多糖の結合体
|
EP2493499A1
(de)
|
2009-10-27 |
2012-09-05 |
Novartis AG |
Modifizierte meningokokken-fhbp-polypeptide
|
SG10201407096RA
(en)
|
2009-10-30 |
2014-12-30 |
Novartis Ag |
Purification of staphylococcus aureus type 5 and type 8 capsular saccharides
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
GB201003333D0
(en)
|
2010-02-26 |
2010-04-14 |
Novartis Ag |
Immunogenic proteins and compositions
|
GB201003922D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Conjugation process
|
GB201005625D0
(en)
|
2010-04-01 |
2010-05-19 |
Novartis Ag |
Immunogenic proteins and compositions
|
JP2013532008A
(ja)
|
2010-05-28 |
2013-08-15 |
テトリス オンライン インコーポレイテッド |
対話式ハイブリッド非同期コンピュータ・ゲーム・インフラストラクチャ
|
EP2585106A1
(de)
|
2010-06-25 |
2013-05-01 |
Novartis AG |
Kombinationen aus meningokokken-faktor-h-bindenden proteinen
|
GB201101665D0
(en)
|
2011-01-31 |
2011-03-16 |
Novartis Ag |
Immunogenic compositions
|
WO2012072769A1
(en)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Pneumococcal rrgb epitopes and clade combinations
|
US20130315959A1
(en)
|
2010-12-24 |
2013-11-28 |
Novartis Ag |
Compounds
|
ES2612511T3
(es)
|
2011-01-27 |
2017-05-17 |
Glaxosmithkline Biologicals Sa |
Nanoemulsiones de adyuvante con inhibidores de cristalización
|
WO2012131504A1
(en)
|
2011-03-02 |
2012-10-04 |
Pfizer Inc. |
Pcsk9 vaccine
|
KR20140026392A
(ko)
|
2011-03-02 |
2014-03-05 |
노파르티스 아게 |
저용량의 항원 및/또는 보조제를 갖는 조합 백신
|
GB201103836D0
(en)
|
2011-03-07 |
2011-04-20 |
Glaxosmithkline Biolog Sa |
Conjugation process
|
US10357568B2
(en)
|
2011-03-24 |
2019-07-23 |
Glaxosmithkline Biologicals S.A. |
Adjuvant nanoemulsions with phospholipids
|
EP2511295A1
(de)
|
2011-04-15 |
2012-10-17 |
Institut National De La Sante Et De La Recherche Medicale |
Zusammensetzungen zur Vorbeugung und/oder Behandlung einer Infektion durch einen HIV-1-Virus
|
JP6499446B2
(ja)
|
2011-06-24 |
2019-04-10 |
エピットジェネシス・インコーポレーテッド |
抗原特異的免疫モジュレーターとして選択担体、ビタミン、タンニンおよびフラボノイドの組み合わせを含有する医薬組成物
|
WO2013009564A1
(en)
|
2011-07-08 |
2013-01-17 |
Novartis Ag |
Tyrosine ligation process
|
GB201114923D0
(en)
|
2011-08-30 |
2011-10-12 |
Novartis Ag |
Immunogenic proteins and compositions
|
EP2755683B1
(de)
|
2011-09-14 |
2019-04-03 |
GlaxoSmithKline Biologicals SA |
Verfahren zur herstellung von saccharidprotein-glykokonjugaten
|
RU2636350C2
(ru)
|
2011-11-07 |
2017-11-22 |
Новартис Аг |
МОЛЕКУЛА, СОДЕРЖАЩАЯ SPR0096 и SPR2021
|
EP2592137A1
(de)
|
2011-11-11 |
2013-05-15 |
Novartis AG |
Fermentierungsmedium ohne Bestandteile tierischen Ursprungs zur Herstellung von Diphtherie-Impfstoffen zur menschlichen Impfung
|
DE102011118371B4
(de)
|
2011-11-11 |
2014-02-13 |
Novartis Ag |
Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
|
DE102011122891B4
(de)
|
2011-11-11 |
2014-12-24 |
Novartis Ag |
Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
|
GB2495341B
(en)
|
2011-11-11 |
2013-09-18 |
Novartis Ag |
Fermentation methods and their products
|
CA2858519A1
(en)
|
2011-12-08 |
2013-06-13 |
Novartis Ag |
Clostridium difficile toxin-based vaccine
|
GB201121301D0
(en)
|
2011-12-12 |
2012-01-25 |
Novartis Ag |
Method
|
EP2797624A1
(de)
|
2011-12-29 |
2014-11-05 |
Novartis AG |
Kombinationen aus meningokokken-faktor-h-bindenden proteinen
|
WO2013124473A1
(en)
|
2012-02-24 |
2013-08-29 |
Novartis Ag |
Pilus proteins and compositions
|
US20150132339A1
(en)
|
2012-03-07 |
2015-05-14 |
Novartis Ag |
Adjuvanted formulations of streptococcus pneumoniae antigens
|
US20150125486A1
(en)
|
2012-03-08 |
2015-05-07 |
Novartis Ag |
Adjuvanted formulations of pediatric antigens
|
SA115360586B1
(ar)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
|
US10279026B2
(en)
|
2012-04-26 |
2019-05-07 |
Glaxosmithkline Biologicals Sa |
Antigens and antigen combinations
|
CA2871520C
(en)
|
2012-04-26 |
2020-12-29 |
Novartis Ag |
Antigens from non-typeable h. influenzae
|
US10124051B2
(en)
|
2012-05-22 |
2018-11-13 |
Glaxosmithkline Biologicals Sa |
Meningococcus serogroup X conjugate
|
MX2015002717A
(es)
|
2012-09-06 |
2015-05-15 |
Novartis Ag |
Vacunas combinadas con meningococo del serogrupo b y toxoides de difteria/tetanos/tosferina.
|
RU2015106791A
(ru)
|
2012-10-03 |
2016-11-20 |
Глэксосмитиклайн Байолоджикалз Са |
Иммуногенные композиции
|
EP3620172A1
(de)
|
2012-10-12 |
2020-03-11 |
GlaxoSmithKline Biologicals SA |
Unvernetzte azelluläre pertussis-antigene zur verwendung in kombinationsimpfstoffen
|
LT2925355T
(lt)
|
2012-11-30 |
2018-03-26 |
Glaxosmithkline Biologicals S.A. |
Pseudomonas antigenai ir antigenų deriniai
|
ES2670863T3
(es)
|
2013-02-01 |
2018-06-01 |
Glaxosmithkline Biologicals Sa |
Administración intradérmica de composiciones inmunológicas que comprenden agonistas del receptor de tipo Toll
|
KR20180099912A
(ko)
|
2013-09-08 |
2018-09-05 |
화이자 인코포레이티드 |
나이세리아 메닌지티디스 조성물 및 그의 방법
|
US11708411B2
(en)
|
2013-12-20 |
2023-07-25 |
Wake Forest University Health Sciences |
Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
|
WO2015110940A2
(en)
|
2014-01-21 |
2015-07-30 |
Pfizer Inc. |
Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
RU2743793C1
(ru)
|
2014-01-21 |
2021-02-26 |
Пфайзер Инк. |
Капсульные полисахариды Streptococcus pneumoniae и их конъюгаты
|
EP3607966A1
(de)
|
2014-01-21 |
2020-02-12 |
Pfizer Inc |
Immunogene zusammensetzungen mit konjugierten kapselsaccharid-antigenen und verwendungen davon
|
EP3443983B1
(de)
|
2014-02-14 |
2022-07-20 |
Pfizer Inc. |
Immunogene glykoproteinkonjugate
|
CA2940447C
(en)
|
2014-02-28 |
2023-07-11 |
Glaxosmithkline Biologicals Sa |
Modified meningococcal fhbp polypeptides
|
EP3034516A1
(de)
|
2014-12-19 |
2016-06-22 |
Novartis AG |
Reinigung von Streptokokkenkapselpolysaccharid
|
BR112017013891B1
(pt)
|
2015-01-15 |
2024-01-30 |
Pfizer Inc |
Composições imunogênicas para uso em vacinas pneumocócicas
|
AU2016215175B2
(en)
|
2015-02-06 |
2021-09-16 |
Heat Biologics, Inc. |
Vector co-expressing vaccine and costimulatory molecules
|
WO2016184962A1
(en)
|
2015-05-19 |
2016-11-24 |
Innavirvax |
Treatment of hiv-infected individuals
|
WO2016184963A1
(en)
|
2015-05-19 |
2016-11-24 |
Innavirvax |
Treatment of hiv-infected individuals
|
EP3109255A1
(de)
|
2015-06-26 |
2016-12-28 |
Institut National De La Recherche Agronomique |
Immunogene zusammensetzung
|
CA2936378A1
(en)
|
2015-07-21 |
2017-01-21 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
GB201518684D0
(en)
|
2015-10-21 |
2015-12-02 |
Glaxosmithkline Biolog Sa |
Vaccine
|
WO2017085586A1
(en)
|
2015-11-20 |
2017-05-26 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
CU24609B1
(es)
|
2015-12-04 |
2022-06-06 |
Dana Farber Cancer Inst Inc |
Proteína de fusión que comprende una proteína de subunidad de ferritina monomérica unida a una proteína de dominio alfa 3 de mic
|
US11612664B2
(en)
|
2016-04-05 |
2023-03-28 |
Gsk Vaccines S.R.L. |
Immunogenic compositions
|
US10577409B2
(en)
|
2016-05-26 |
2020-03-03 |
Sagabio Co., Ltd. |
Monoclonal antibody inhibiting immunosuppressive functions of pathogens, antigen-binding fragment thereof, and hybridomas producing such antibody
|
HUE048588T2
(hu)
|
2016-06-09 |
2020-08-28 |
Sagabio Co Ltd |
Helicobacter pylori immunszuppresszív funkcióit gátló monoklonális ellenanyag, annak antigénkötõ fragmentuma és ilyen ellenanyagot termelõ hibridómák
|
EP3254732A1
(de)
|
2016-06-09 |
2017-12-13 |
Sagabio Co., Ltd. |
Immunopotenzierende zusammensetzungen, die einen anti helicobacter pylori antikörper enthalten
|
CA3035320A1
(en)
|
2016-09-02 |
2018-03-08 |
Glaxosmithkline Biologicals Sa |
Vaccines for neisseria gonorrhoeae
|
IL296165B2
(en)
|
2016-10-07 |
2023-10-01 |
Enterome S A |
Immunogenic compounds for cancer treatment
|
CN117801069A
(zh)
|
2016-10-07 |
2024-04-02 |
恩特罗姆公司 |
用于癌症疗法的免疫原性化合物
|
CA3040123A1
(en)
|
2016-10-11 |
2018-04-19 |
University Of Miami |
Vectors and vaccine cells for immunity against zika virus
|
US20210108002A1
(en)
|
2016-12-06 |
2021-04-15 |
Glaxosmithkline Biologicals Sa |
Purification Process For Capsular Polysaccharide
|
RU2762723C2
(ru)
|
2017-01-20 |
2021-12-22 |
Пфайзер Инк. |
Иммуногенные композиции для применения в пневмококковых вакцинах
|
KR102650073B1
(ko)
|
2017-01-31 |
2024-03-20 |
머크 샤프 앤드 돔 엘엘씨 |
스트렙토코커스 뉴모니아 혈청형 19f 유래의 협막 다당류 단백질 접합체의 제조 방법
|
KR20220011796A
(ko)
|
2017-01-31 |
2022-01-28 |
화이자 인코포레이티드 |
네이세리아 메닌기티디스 조성물 및 그의 방법
|
US11548930B2
(en)
|
2017-04-04 |
2023-01-10 |
Heat Biologics, Inc. |
Intratumoral vaccination
|
BR112020004509A8
(pt)
|
2017-09-07 |
2023-01-31 |
Merck Sharp & Dohme |
Conjugado polissacarídeo-proteína carreadora, composição imunogênica compreendendo o mesmo e uso do referido conjugado
|
KR102573200B1
(ko)
|
2017-12-06 |
2023-08-31 |
머크 샤프 앤드 돔 엘엘씨 |
스트렙토코쿠스 뉴모니아에 폴리사카라이드-단백질접합체를 포함하는 조성물 및 그의 사용 방법
|
LT3773689T
(lt)
|
2018-04-11 |
2023-01-25 |
Enterome S.A. |
Antigeniniai peptidai, skirti vėžio prevencijai ir gydymui
|
EP3773673A2
(de)
|
2018-04-11 |
2021-02-17 |
Enterome S.A. |
Immunogene verbindungen zur behandlung von fibrose, autoimmunerkrankungen und entzündungen
|
BR112021000529A2
(pt)
|
2018-07-19 |
2021-04-06 |
Glaxosmithkline Biologicals S.A. |
Processos para preparar polissacarídeos secos
|
EP3607967A1
(de)
|
2018-08-09 |
2020-02-12 |
GlaxoSmithKline Biologicals S.A. |
Modifizierte meningokokken fhbp polypeptide
|
US11260119B2
(en)
|
2018-08-24 |
2022-03-01 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
CA3120922A1
(en)
|
2018-12-12 |
2020-06-18 |
Pfizer Inc. |
Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
|
PE20211888A1
(es)
|
2018-12-19 |
2021-09-22 |
Merck Sharp & Dohme |
Composiciones que comprenden conjugados de polisacarido de streptococcus pneumoniae con proteina y sus metodos de uso
|
CA3129425A1
(en)
|
2019-02-11 |
2020-08-20 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
JP7239509B6
(ja)
|
2019-02-22 |
2023-03-28 |
ファイザー・インク |
細菌多糖類を精製するための方法
|
EP3952906A1
(de)
|
2019-04-10 |
2022-02-16 |
Pfizer Inc. |
Immunogene zusammensetzungen mit konjugierten kapselförmigen saccharidantigenen, kits damit und verwendungen davon
|
CA3139257A1
(en)
|
2019-05-10 |
2020-11-19 |
Glaxosmithkline Biologicals Sa |
Conjugate production
|
BR112022001654A2
(pt)
|
2019-07-31 |
2022-07-12 |
Sanofi Pasteur Inc |
Composições conjugadas de proteinas de polissacarídeos pneumocócicos multivalentes e métodos de utilização dos mesmos
|
BR112022004921A2
(pt)
|
2019-09-27 |
2022-07-19 |
Pfizer |
Composições para neisseria meningitidis e métodos das mesmas
|
WO2021074389A1
(en)
|
2019-10-16 |
2021-04-22 |
Enterome S.A. |
Immunogenic compounds for treatment of adrenal cancer
|
EP4051696A1
(de)
|
2019-11-01 |
2022-09-07 |
Pfizer Inc. |
Escherichia-zusammensetzungen und verfahren dafür
|
HRP20240116T1
(hr)
|
2019-11-15 |
2024-04-12 |
Enterome S.A. |
Antigeni peptidi, namijenjeni sprječavanju i liječenju zloćudnih tumora b-stanica
|
JP2023503086A
(ja)
|
2019-11-22 |
2023-01-26 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
細菌サッカリド複合糖質ワクチンの用法及び用量
|
MX2022010355A
(es)
|
2020-02-21 |
2022-09-21 |
Pfizer |
Purificacion de sacaridos.
|
CA3173729A1
(en)
|
2020-02-23 |
2021-08-26 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
US20230250142A1
(en)
|
2020-06-12 |
2023-08-10 |
Glaxosmithkline Biologicals Sa |
Dock tag system
|
GB202013262D0
(en)
|
2020-08-25 |
2020-10-07 |
Glaxosmithkline Biologicals Sa |
Vaccine Composition
|
CA3199094A1
(en)
|
2020-10-22 |
2022-04-28 |
Pfizer Inc. |
Methods for purifying bacterial polysaccharides
|
TW202227467A
(zh)
|
2020-10-27 |
2022-07-16 |
美商輝瑞大藥廠 |
大腸桿菌組合物及其方法
|
EP4240410A1
(de)
|
2020-11-04 |
2023-09-13 |
Pfizer Inc. |
Immunogene zusammensetzungen zur verwendung in pneumokokkenimpfstoffen
|
US20220202923A1
(en)
|
2020-12-23 |
2022-06-30 |
Pfizer Inc. |
E. coli fimh mutants and uses thereof
|
TW202245835A
(zh)
|
2021-02-04 |
2022-12-01 |
美商默沙東有限責任公司 |
用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
|
EP4070814A1
(de)
|
2021-04-07 |
2022-10-12 |
Lama France |
Sars-cov-2-polypeptide und verwendungen davon
|
WO2022234416A1
(en)
|
2021-05-03 |
2022-11-10 |
Pfizer Inc. |
Vaccination against pneumoccocal and covid-19 infections
|
CA3218544A1
(en)
|
2021-05-03 |
2022-11-10 |
Pfizer Inc. |
Vaccination against bacterial and betacoronavirus infections
|
AU2022281543A1
(en)
|
2021-05-28 |
2023-11-23 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
US20220387576A1
(en)
|
2021-05-28 |
2022-12-08 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2023135515A1
(en)
|
2022-01-13 |
2023-07-20 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2023161817A1
(en)
|
2022-02-25 |
2023-08-31 |
Pfizer Inc. |
Methods for incorporating azido groups in bacterial capsular polysaccharides
|
WO2023187127A1
(en)
|
2022-03-31 |
2023-10-05 |
Enterome S.A. |
Antigenic peptides for prevention and treatment of cancer
|
WO2023218322A1
(en)
|
2022-05-11 |
2023-11-16 |
Pfizer Inc. |
Process for producing of vaccine formulations with preservatives
|
GB202208093D0
(en)
|
2022-06-01 |
2022-07-13 |
Glaxosmithkline Biologicals Sa |
Immunogenic composition
|
GB202208089D0
(en)
|
2022-06-01 |
2022-07-13 |
Glaxosmithkline Biologicals Sa |
Immunogenic composition
|
WO2024084397A1
(en)
|
2022-10-19 |
2024-04-25 |
Pfizer Inc. |
Vaccination against pneumoccocal and covid-19 infections
|